The top management of Danish pharmaceutical giant Novo Nordisk reportedly travelled to China in June to explore the possibility of partnering with a local manufacturer, according to the Danish business newspaper Finans. During the visit, Novo Nordisk executives are said to have met with a potential Chinese partner as the company explores expanding its manufacturing capacity in one of its most strategically important growth markets. The growing global demand for GLP-1 medicines has prompted pharmaceutical companies to expand production capacity, and two Danish analysts told Finans that exploring a local manufacturing partnership in China would be a logical step. The production of Wegovy requires large quantities of semaglutide, making manufacturing capacity a key challenge as demand continues to grow. Novo Nordisk declined to comment on the reported China plans when contacted by Finans.